Home・Akcijų sąrašas・Arvinas Inc

Arvinas Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.94 11.75

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

9.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	9.8M -58M
Pardavimai	6.1M 16M
Pelnas, tenkantis vienai akcijai	-0.9
Pelno marža	-369.231
Darbuotojai	246
EBITDA	9.6M -56M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+80.77% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-103M 520M
Ankstesnė atidarymo kaina	-2.81
Ankstesnė uždarymo kaina	8.94

Naujienos nuotaikos

By Acuity

43%

57%

160 / 340 reitingas Healthcare

Arvinas Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-04 20:02; UTC

Social Media

News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

2026-08-03 19:46; UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

2026-07-31 20:06; UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

2026-07-29 16:36; UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

2026-07-28 20:06; UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

2026-07-24 19:26; UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

2026-07-22 20:06; UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

2026-07-21 20:06; UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Akcijų palyginimas

Kainos pokytis

Arvinas Inc Prognozė

Kainos tikslas

By TipRanks

80.77% į viršų

12 mėnesių prognozė

Vidutinis 14.57 USD 80.77%

Aukščiausias 20 USD

Žemiausias 6 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arvinas Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Arvinas Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

160 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.